Loading...

Profound Medical Corp.

PRN.TOTSX
HealthcareMedical - Devices
$5.95
$-0.05(-0.83%)

Profound Medical Corp. (PRN.TO) Stock Overview

Explore Profound Medical Corp.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
48.35%
48.35%
Profit Growth
$-1.08
2.64%
EPS Growth
$-1.08
14.07%
Operating Margin
-162.88%
15.54%
ROE
-63.01%
2.64%
Dividend Yield
0.00%
Analyst Recommendations data is not available for PRN.TOAnalyst Recommendations details for PRN.TO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

CEO

Dr. Arun Swarup Menawat MBA, Ph.D.

Employees

142

Headquarters

2400 Skymark Avenue, Mississauga, ON

Founded

2018

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.